EXAS240719C62500
- 0.03
- 0.000.00%
Exact Sciences Newsroom
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
Exact Sciences Schedules Second Quarter 2024 Earnings Call
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S.
People Are Feeling Stuck in Their Jobs. Bosses Are Starting to Worry. -- WSJ
By Chip Cutter You are likely not getting a big promotion this year. So how about a job swap? Many workers say they are considering that question as they feel stuck in their roles. With the white-co
Exact Sciences Price Target Cut to $72.00/Share From $80.00 by Evercore ISI Group
Exact Sciences Price Target Cut to $72.00/Share From $80.00 by Evercore ISI Group
Exact Sciences Is Maintained at Outperform by Evercore ISI Group
Exact Sciences Is Maintained at Outperform by Evercore ISI Group
Exact Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 67.42% Evercore ISI Group $80 → $72 Maintains Outperform 06/27/2024 62.77% BTIG $80 → $70 Maint
Evercore Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $72
Evercore analyst Vijay Kumar maintains $Exact Sciences(EXAS.US)$ with a buy rating, and adjusts the target price from $90 to $72.According to TipRanks data, the analyst has a success rate of 47.4% and
Express News | Geneoscopy: Confident Litigation Will Not Delay Commercial Launch of Colosense
Express News | Geneoscopy: Files Counterclaims Against Exact Sciences
Exact Sciences Initiated at Sector Outperform at Scotiabank on Advanced Diagnostics
Exact Sciences Initiated at Sector Outperform by Scotiabank
Exact Sciences Initiated at Sector Outperform by Scotiabank
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $75
Jefferies analyst Tycho Peterson maintains $Exact Sciences(EXAS.US)$ with a buy rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success rate of 55.3% and a
Scotiabank Initiates Exact Sciences at Sector Outperform With $70 Price Target
Exact Sciences (EXAS) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $66 to $100. Price: 44.00, Change: -0.16, Percent Change: -0.36
Express News | Exact Sciences Corp : Btig Cuts Target Price to $70 From $80
Express News | Exact Sciences Corp : Scotiabank Initiates Coverage With Sector Outperform Rating; Target Price $70
Top Gap Ups and Downs on Wednesday: SAP, RACE, FDX and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Scotiabank Initiates Exact Sciences(EXAS.US) With Buy Rating, Announces Target Price $70
Scotiabank analyst Sung Ji Nam initiates coverage on $Exact Sciences(EXAS.US)$ with a buy rating, and sets the target price at $70.According to TipRanks data, the analyst has a success rate of 45.0% a
Exact Sciences Gains as TD Cowen Sees 25% Price Hike for Next-gen Cologuard
Expert Outlook: Exact Sciences Through The Eyes Of 5 Analysts
5 analysts have expressed a variety of opinions on Exact Sciences (NASDAQ:EXAS) over the past quarter, offering a diverse set of opinions from bullish to bearish.Summarizing their recent assessments,
BTIG Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $70
BTIG analyst Mark Massaro maintains $Exact Sciences(EXAS.US)$ with a buy rating, and adjusts the target price from $80 to $70.According to TipRanks data, the analyst has a success rate of 29.1% and a